Go Pro
→ Sam Altman backs small company that could save U.S. power grid (From Altimetry) (Ad)tc pixel
Jason McCarthy

Jason McCarthy Analyst Performance

Senior Managing Director, Head of Biotechnology Research at Maxim Group

Jason McCarthy is a stock analyst at Maxim Group focused in the medical sector, covering 115 publicly traded companies. Over the past year, Jason McCarthy has issued 40 stock ratings, including buy and hold recommendations. While full access to Jason McCarthy's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jason McCarthy's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
684 Last 10 Years
Buy Recommendations
89.15% 600 Buy Ratings
Companies Covered
115 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy89.2%600 ratings
Hold10.8%73 ratings
Sell0.0%0 ratings

Out of 673 total stock ratings issued by Jason McCarthy at Maxim Group, the majority (89.2%) have been Buy recommendations, followed by 10.8% Hold.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
78.3% of companies on NASDAQ
90 companies
NYSEAMERICAN
9.6% of companies on NYSEAMERICAN
11 companies
OTCMKTS
7.0% of companies on OTCMKTS
8 companies
NYSE
4.3% of companies on NYSE
5 companies
TSE
0.9% of companies on TSE
1 company

Jason McCarthy, an analyst at Maxim Group, currently covers 115 companies listed on NASDAQ, NYSEAMERICAN, OTCMKTS, NYSE and TSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
110 companies		95.7%
Manufacturing
3 companies		2.6%
Finance
1 company		0.9%
Industrials
1 company		0.9%

Jason McCarthy of Maxim Group specializes in stock coverage within the Medical sector, with additional focus on Manufacturing and Finance companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
53 companies		46.1%
PHARMACEUTICAL PREPARATIONS
21 companies		18.3%
MED - DRUGS
18 companies		15.7%
MED PRODUCTS
6 companies		5.2%
BIOTECHNOLOGY
3 companies		2.6%
MEDICAL SERVICES
2 companies		1.7%
Miscellaneous
2 companies		1.7%
SURGICAL & MEDICAL INSTRUMENTS
2 companies		1.7%
SURGICAL, MEDICAL, AND DENTAL INSTRUMENTS AND SUPPLIES
1 company		0.9%
FIN - MISC SVCS
1 company		0.9%
MED INSTRUMENTS
1 company		0.9%
DIAGNOSTIC SUBSTANCES
1 company		0.9%
PROTECTION - SFTY
1 company		0.9%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company		0.9%
MED - GENERIC DRG
1 company		0.9%
MEDICAL LABORATORIES
1 company		0.9%

About Jason McCarthy

Jason McCarthy, Ph.D. is a Senior Managing Director and Head of Biotechnology Research at Maxim Group. Dr. McCarthy joined Maxim Group in July 2014. Prior to joining Maxim he received his doctoral degree in Biomedical Sciences at the Albert Einstein College of Medicine. Dr. McCarthy also holds a Master’s degree in both Biomedical Research (Albert Einstein College of Medicine) and Molecular Biology (Adelphi University), as well as a B.S. in Biochemistry from Stony Brook University.

Jason McCarthy's Ratings History at Maxim Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
7/20/2026Upgrade$11.01$30.00Buy
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
7/20/2026Initiated Coverage$0.86$4.00Buy
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
6/17/2026Upgrade$0.37Buy
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
6/16/2026Lower Price Target$0.68$4.00Buy
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
6/10/2026Boost Price Target$13.67$35.00Buy
Rezolute, Inc. stock logo
RZLT
Rezolute
6/2/2026Boost Price Target$4.00$14.00Buy
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
5/26/2026Reiterated Rating$1.41$5.00Buy
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
5/18/2026Initiated Coverage$5.50$20.00Buy
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
5/15/2026Boost Price Target$10.18$20.00Buy
Rezolute, Inc. stock logo
RZLT
Rezolute
5/14/2026Boost Price Target$3.49$10.00Buy
Imunon, Inc. stock logo
IMNN
Imunon
4/17/2026Set Price Target$3.09$10.00Buy
Imunon, Inc. stock logo
IMNN
Imunon
4/17/2026Initiated Coverage$3.13Buy
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
4/8/2026Downgrade$3.80Hold
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
4/8/2026Downgrade$0.82Hold
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
3/31/2026Upgrade$0.20$1.00Buy
MediciNova, Inc. stock logo
MNOV
MediciNova
3/23/2026Reiterated Rating$1.56$6.00Buy
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
3/12/2026Boost Price Target$5.37$10.00Buy
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
3/10/2026Upgrade$2.75Buy
Polaryx Therapeutics, Inc. stock logo
PLYX
Polaryx Therapeutics
2/27/2026Initiated Coverage$3.19$10.00Buy
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
1/23/2026Downgrade$2.92Hold
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
12/17/2025Reiterated Rating$0.86Hold
Rezolute, Inc. stock logo
RZLT
Rezolute
12/12/2025Set Price Target$1.60$4.00
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
12/4/2025Boost Price Target$23.17$50.00Buy
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
11/26/2025Upgrade$0.36Hold
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
11/26/2025Initiated Coverage$9.75$45.00Buy
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
11/19/2025Reiterated Rating$1.84Hold
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
11/3/2025Downgrade$0.13Hold
Abpro Holdings Inc. stock logo
ABP
Abpro
10/21/2025Downgrade$0.20Hold
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
10/7/2025Boost Price Target$2.02$7.00Buy
HIND
Vyome
10/2/2025Reiterated Rating$5.50$15.00Buy
HIND
Vyome
10/2/2025Reiterated Rating$5.36$15.00Buy
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
9/30/2025Upgrade$8.31$37.50Buy
Azitra, Inc. stock logo
AZTR
Azitra
9/24/2025Lower Price Target$0.73$4.00Buy
Rezolute, Inc. stock logo
RZLT
Rezolute
9/18/2025Boost Price Target$8.33$20.00Buy
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
9/12/2025Upgrade$7.74$20.00Buy
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
9/11/2025Boost Price Target$14.06$35.00Buy
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
9/4/2025Upgrade$1.26$4.00Buy
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
8/18/2025Lower Price Target$13.78$75.00Buy
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
8/15/2025Lower Price Target$10.80$40.00Buy
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
7/23/2025Downgrade$0.71Hold
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it? (Ad)

BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel

Get the name, the ticker, and exactly how to buy it
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
7/18/2025Initiated Coverage$45.20$200.00Buy
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
7/16/2025Boost Price Target$1.87$7.00Buy
INmune Bio, Inc. stock logo
INMB
INmune Bio
7/2/2025Lower Price Target$2.34$8.00Buy
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
5/23/2025Downgrade$0.72Hold
MetaVia Inc. stock logo
MTVA
MetaVia
5/19/2025Lower Price Target$7.48$33.00Buy
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
5/19/2025Initiated Coverage$11.80$60.00Buy
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
5/14/2025Reiterated Rating$0.24Hold
Primis Financial Corp. stock logo
FRST
Primis Financial
5/12/2025Initiated Coverage$8.96$1.00Buy
Promis Neurosciences stock logo
PMN
Promis Neurosciences
5/12/2025Initiated Coverage$12.41$75.00Buy
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
5/8/2025Reiterated Rating$0.81Hold
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
5/8/2025Boost Price Target$4.34$20.00Buy
Kairos Pharma, Ltd. stock logo
KAPA
Kairos Pharma
3/27/2025Initiated Coverage$0.93$4.00Buy
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3/25/2025Upgrade$26.50$100.00Buy
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
3/25/2025Reiterated Rating$1.45Hold
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
3/21/2025Initiated Coverage$3.15$10.00Buy
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
3/10/2025Lower Price Target$0.65$3.00Buy
Abpro Holdings Inc. stock logo
ABP
Abpro
2/24/2025Initiated Coverage$23.75$120.00Buy
INmune Bio, Inc. stock logo
INMB
INmune Bio
2/13/2025Boost Price Target$9.30$30.00Buy
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2/12/2025Downgrade$0.51Hold
Novogen Limited stock logo
KZIA
Novogen
2/6/2025Initiated Coverage$7.00$15.00Buy
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
1/30/2025Boost Price Target$4.57$12.00Buy
OS Therapies Incorporated stock logo
OSTX
OS Therapies
1/16/2025Boost Price Target$4.31$15.00Buy
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
1/10/2025Upgrade$40.62$140.00Buy
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
12/17/2024Initiated Coverage$2.95$10.00Buy
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
12/12/2024Initiated Coverage$2.27$8.00Buy
OS Therapies Incorporated stock logo
OSTX
OS Therapies
11/26/2024Initiated Coverage$2.02$8.00Buy
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
11/7/2024Initiated Coverage$292.00$1,200.00Buy
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
10/31/2024Reiterated Rating$0.62Hold
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
10/25/2024Upgrade$9.07$25.00Buy
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
9/10/2024Upgrade$85.20$300.00Buy
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
8/16/2024Reiterated Rating$0.69Hold
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
8/14/2024Reiterated Rating$3.60Hold

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Top Stock Recommendations by Brokerage